摘要
目的观察和探讨泰素单药或联合蒽环类药物的Weekly方案在乳腺癌新辅助化疗应用中的临床疗效. 方法对42例乳腺癌患者,确诊后立即行以泰素(TXL)单药或联合表阿霉素(EPI)的Weekly方案新辅助化疗,术前术后各3周,化疗1～4个疗程,每疗程间隔3周.术前化疗无效者术后改用其他化疗方案.结果术前无达到临床完全缓解(CR)者.本组术前有效35例,其中PR 6例、MR 29例,有效率83.3%.10例行保乳手术,32例行改良根治术.化疗过程中,没有出现严重的化疗毒性.结论 Weekly方案治疗乳腺癌副作用小,疗效肯定,术前应用可为手术提供更多的选择机会,并为筛选敏感的化疗药物提供参考,是一种安全有效的辅助治疗方法,值得临床推广和应用.
Objective To explore the treatment protocol and evaluate the outcome of Weekly paclitaxel administration with or without epirubicin in breast cancer. Methods Total of 42 female patients with breast cancer in different stage were enrolled into the research , and were treated with Weekly paclitaxel administration with or without epirubicin immediately after pathological diagnosis. After 3 weeks operation was preformed in all patients , the administration lasted 1 to 4 circles with 3 weeks pause and would be changed if the patients have no response to it. Results No CR was acquired in 3 weeks treatment before the operation , but 6 and 29 of 42 patients were PR , and MR respectively ,the total response rate was 83.3%. The breast conservative surgery was performed in 10 patients and the modified radical resection was performed in 32 patients. No serious side - effect was observed in all patients. Conclusion Weekly paclitaxel administration is a safe and effective administration for breast cancer, which also can supply reliable foundation for operation and chemical treatments after operation. Therefore, it is warranted for wide use.
出处
《现代肿瘤医学》
CAS
2005年第5期649-650,共2页
Journal of Modern Oncology
基金
陕西省自然科学基金资助项目(编号:2003c2053)
关键词
乳腺癌
新辅助化疗
临床疗效
breast cancer
new adjuvant chemotheropy
clinical outcome
